HBM HOLDINGS-B(02142) signs global strategic cooperation and licensing agreement with Bayer Pharmaceutical Company.
Boehringer Ingelheim-B (02142) announced that on December 17, 2025, the company has entered into a long-term global strategic partnership and licensing agreement with Roche, aiming to discover and develop a new generation of multi-specific antibodies.
HBM Holdings-B (02142) announced that on December 17, 2025, the company has entered into a long-term global strategic partnership and licensing agreement with Roche, aimed at discovering and developing a new generation of multispecific antibodies.
According to the agreement, HBM Holdings-B will collaborate with Roche to advance and accelerate the discovery of multispecific antibodies. In return, HBM Holdings-B will receive a total payment of $90 million. If Roche chooses to advance all potential projects, the company may also receive up to $1.035 billion in development and commercial milestone payments, as well as tiered royalties.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
